These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 1783775)

  • 1. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody.
    Gorelick KJ; Chmel H
    Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
    Barriere SL; Guglielmo BJ
    Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Calandra T; Baumgartner JD; Glauser MP
    Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies to endotoxin in the management of sepsis.
    Fang KC
    West J Med; 1993 Apr; 158(4):393-9. PubMed ID: 8317126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
    Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
    N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Life-saving immunotherapy with cross-reactive monoclonal antibodies against endotoxin: a critical evaluation of experimental and clinical studies.
    Cornelissen JJ; Schellekens JF; Kraaijeveld CA; Verhoef J
    Neth J Med; 1991 Oct; 39(3-4):170-6. PubMed ID: 1791879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy, safety, and therapeutic usage of HA-1A and E5 in the treatment of gram-negative sepsis.
    Quintiliani R; Cooper B; Maderazo E; Nightingale C
    Hosp Formul; 1992 Jan; 27(1):49-52, 54, 57-60. PubMed ID: 10116116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group.
    Greenman RL; Schein RM; Martin MA; Wenzel RP; MacIntyre NR; Emmanuel G; Chmel H; Kohler RB; McCarthy M; Plouffe J
    JAMA; 1991 Aug; 266(8):1097-102. PubMed ID: 1865542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Projected impact of monoclonal anti-endotoxin antibody therapy.
    Bates DW; Lee TH
    Arch Intern Med; 1994 Jun; 154(11):1241-9. PubMed ID: 8203991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivity of monoclonal antibody E5 with endotoxin. II. Binding to short- and long-chain smooth lipopolysaccharides.
    Parent JB; Gazzano-Santoro H; Wood DM; Lim E; Pruyne PT; Trown PW; Conlon PJ
    Circ Shock; 1992 Sep; 38(1):63-73. PubMed ID: 1382882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of monoclonal antibody therapy in the treatment of infectious disease.
    Chmel H
    Am J Hosp Pharm; 1990 Nov; 47(11 Suppl 3):S11-5. PubMed ID: 2275476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive immunotherapy of gram-negative sepsis: use of monoclonal antibodies to lipopolysaccharide.
    Fink MP
    Crit Care Med; 1993 Feb; 21(2 Suppl):S32-9. PubMed ID: 8428494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis.
    Daifuku R; Panacek EA; Haenftling K; Swenson WK; Prescott AW; Johnson JL
    Hum Antibodies Hybridomas; 1993 Jan; 4(1):36-9. PubMed ID: 8431557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group.
    Bone RC; Balk RA; Fein AM; Perl TM; Wenzel RP; Reines HD; Quenzer RW; Iberti TJ; Macintyre N; Schein RM
    Crit Care Med; 1995 Jun; 23(6):994-1006. PubMed ID: 7774238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of endotoxemia and septicemia.
    Baumgartner JD; Glauser MP
    Immunobiology; 1993 Apr; 187(3-5):464-77. PubMed ID: 8330909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiendotoxin therapies for septic shock.
    Corriveau CC; Danner RL
    Infect Agents Dis; 1993 Feb; 2(1):44-52. PubMed ID: 8162353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind phase II study of anti-endotoxin antibody (E5) as adjuvant therapy in humans with serious gram-negative infections.
    Greenberg RN; Wilson KM; Kunz AY; Wedel NI; Gorelick KJ
    Prog Clin Biol Res; 1991; 367():179-86. PubMed ID: 1924426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibody therapy for gram-negative sepsis: principles, applications, and controversies.
    Mehra IV; Gottlieb JE; Nash DB
    Pharmacotherapy; 1993; 13(2):128-34. PubMed ID: 8469619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HA-1A. A human monoclonal antibody for the treatment of gram-negative sepsis.
    Smith CR; Straube RC; Ziegler EJ
    Infect Dis Clin North Am; 1992 Mar; 6(1):253-66. PubMed ID: 1578120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivity of monoclonal antibody E5 with endotoxin. I. Binding to lipid A and rough lipopolysaccharides.
    Wood DM; Parent JB; Gazzano-Santoro H; Lim E; Pruyne PT; Watkins JM; Spoor ES; Reardan DT; Trown PW; Conlon PJ
    Circ Shock; 1992 Sep; 38(1):55-62. PubMed ID: 1394865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.